Director/PDMR Shareholding

Argent Biopharma Limited
15 October 2024
 

 

15 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

PDMR Notification

 

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), advises of the following transaction which took place on 15 October 2024 whereby, Roby Zomer (Argent BioPharma's Managing Director & CEO) was issued 4,000,000 fully paid ordinary shares in Company at a price of A$0.41 each following the approval of resolution 1 at a general meeting of shareholders on 1 October 2024.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Roby Zomer

2

Reason for the notification

 

(a)

Position

 

Managing Director and Chief Executive Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

Argent BioPharma Ltd

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU0000326647

(c)

Nature of transaction

Shares issued in accordance with the passing of resolution 1 at a general meeting held 1 October 2024.

(d)

Currency

Price

Volume

Total


AUD

0.41

4,000,000

$1,640,000


Aggregated information


AUD

0.41

4,000,000

$1,640,000

(e)

Date of transaction

 

15 October 2024

(f)

Place of transaction

 

Outside a trading venue

 

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Limited               

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma Limited

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings